Etobicoke Site

The Etobicoke Site is a major pharmaceutical manufacturing facility located in Etobicoke, Ontario, Canada, and serves as a primary production hub for Apotex Inc., the country's largest generic drug manufacturer. The facility is dedicated to the large-scale manufacturing of solid oral dosage forms, including a wide array of generic tablets and capsules that address critical therapeutic areas such as cardiovascular health, central nervous system disorders, and metabolic diseases. Licensed by both Health Canada and the U.S. FDA, the site plays a vital role in the global supply of affordable medicines, despite having faced historical regulatory challenges regarding Good Manufacturing Practices (GMP). Following the acquisition of Apotex by SK Capital Partners in 2023, the Etobicoke Site continues to operate as a key asset in the company's international manufacturing network. The facility is part of a broader campus of sites in the Greater Toronto Area that support Apotex's mission to provide high-quality, accessible healthcare solutions.